Rigel Pharma (RIGL) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Rigel Announces Third Quarter 2019 Financial Results
November 5, 2019 4:01 PM ESTSOUTH SAN FRANCISCO, Calif., Nov. 5, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter ended September 30, 2019, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets, for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
"We continue to demonstrate progress in all of the key value drivers for Rigel," said Raul Rodriguez, Rigel's president and CEO. "Our commercial business continues to expand with U.S. sales increasing 15% quarter over quarter. We are moving forward with... More
